Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Yabao Pharmaceutical financials data including stock price, CreditSafe score, income statement, balance sheet, cash flow, and acquistions and subsidiaries.

Stock Price



Market Capitalization

¥4 B



¥2.8 B

FY, 2023

CreditSafe Score

Score changed on Jul 22, 2024
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn more

Financial Statements

CNYFY, 2018FY, 2019FY, 2020FY, 2021FY, 2022FY, 2023
Cost of goods sold1.2B1.1B1.1B1.1B1.2B1.2B
Gross profit1.7B1.9B1.5B1.7B1.5B1.6B
Gross profit margin, %63.5%59.9%62.5%56.1%57.9%
Operating expense total1.2B1.4B1.2B1.3B1.1B1.3B
Depreciation and amortization168.7M434.6M171.7M169.2M207.1M163.6M
EBITDA margin, %17.8%11.5%12.8%12.8%13.1%
EBIT margin, %3.6%6.6%7.7%5.2%7.9%
Interest income4.6M6.6M4.0M8.5M8.2M9.5M
Interest expense34.8M48.0M32.6M22.6M18.8M12.3M
Pre tax profit330.0M49.9M127.4M201.6M125.6M219.0M
Income tax expense45.9M39.1M18.4M17.8M21.0M39.1M
Net Income284.0M10.8M109.0M183.8M104.6M179.9M

Acquisitions & Subsidiaries

Company nameDateDeal size
LoremDec 23, 2021$40.0M
IpsumJan 18, 2022$30.0M
Lorem IpsumFeb 18, 2022$25.0M
DolorOct 21, 2021$60.0M
Premium Content only available in Craft’s Intelligence Portal
View acquisitions and subsidiaries by company, date, and deal size.
Understanding this data enables better supplier & customer negotiations and helps identify potential opportunities or market risks for your firm.
Learn more

Footer menu